| 01.17.2012 |
|
Akorn Provides Financial Guidance for 2012 |
|
Read More |
|
| 12.22.2011 |
|
Akorn Acquires Three Hospital-Based Branded Injectables from Lundbeck |
|
Read More |
|
| 10.07.2011 |
|
Akorn, Inc. Announces Third Quarter 2011 Earnings Release and Conference Call Information |
|
Read More |
|
| 10.06.2011 |
|
Akorn Enters Into an Agreement to Acquire Certain Assets of Kilitch Drugs in India |
|
Read More |
|
| 08.02.2011 |
|
Akorn Reports Second Quarter 2011 Financial Results |
|
Read More |
|
| 08.02.2011 |
|
Akorn to Acquire a Minority Stake in Aciex Therapeutics |
|
Read More |
|
| 06.23.2011 |
|
Akorn, Inc. Announces Second Quarter 2011 Earnings Release and Conference Call Information |
|
Read More |
|
| 06.02.2011 |
|
Akorn Announces Closing of $120 Million of Convertible Senior Notes Due 2016 |
|
Read More |
|
| 05.26.2011 |
|
Akorn Announces Pricing of $100 Million of Convertible Senior Notes Due 2016 |
|
Read More |
|
| 05.25.2011 |
|
Akorn Announces Proposed Offering of $100 Million of Convertible Senior Notes Due 2016 |
|
Read More |
|
| 05.03.2011 |
|
Akorn Reports First Quarter 2011 Financial Results |
|
Read More |
|
| 05.03.2011 |
|
Akorn Enters Into an Agreement to Acquire Advanced Vision Research |
|
Read More |
|
| 04.07.2011 |
|
Akorn, Inc. Announces First Quarter 2011 Earnings Release and Conference Call Information |
|
Read More |
|
| 02.28.2011 |
|
Akorn Reports 2010 Fourth Quarter and Year-End Financial Results - Achieves Annual Core Revenue Growth of 81% - |
|
Read More |
|
| 01.30.2011 |
|
Akorn, Inc. Announces Fourth Quarter 2010 Earnings Release and Conference Call Information |
|
Read More |
|
| 12.28.2010 |
|
Akorn Announces the Sale of the Akorn-Strides Joint Venture Product Portfolio to Pfizer, Inc. |
|
Read More |
|
| 10.31.2010 |
|
Akorn Reports Third Quarter 2010 Results; Core Revenues Increase by 118%; Adjusted EBITDA of $6.3 million; Raises Outlook for 2010 |
|
Read More |
|
| 10.06.2010 |
|
Akorn, Inc. Announces Third Quarter 2010 Earnings Release and Conference Call Information |
|
Read More |
|
| 09.15.2010 |
|
Akorn Announces Launch of Erythromycin Ophthalmic Ointment USP 1 g |
|
Read More |
|
| 08.02.2010 |
|
Akorn Reports Second Quarter 2010 Financial Results -Core Revenues Increase by 138%- -Adjusted EBITDA of $4.2 million; Raises Earnings Outlook for 2010- |
|
Read More |
|
| 08.01.2010 |
|
Akorn, Inc. Announces Second Quarter 2010 Earnings Release and Conference Call Information |
|
Read More |
|
| 05.02.2010 |
|
Akorn Reports First Quarter 2010 Financial Results -Achieves Positive Operating Income from Strong Demand in Core Business- -Raises Outlook for 2010- |
|
Read More |
|
| 04.20.2010 |
|
Akorn Announces FDA Approval to Re-Launch Erythromycin Ophthalmic Ointment USP 3.5 g |
|
Read More |
|
| 04.18.2010 |
|
Akorn, Inc. Announces First Quarter 2010 Earnings Release and Conference Call Information |
|
Read More |
|
| 04.14.2010 |
|
Akorn, Inc. Announces FDA Approval for Hydromorphone Hydrochloride Injection 10mg/mL in 1mL, 5mL and 50mL Doses |
|
Read More |
|
| 03.14.2010 |
|
Akorn Reports 2009 Fourth Quarter and Year-End Financial Results -Achieves Positive Fourth Quarter Cash Flow and Adjusted EBITDA- -Refocuses R&D efforts to Strengthen New Product Pipeline- |
|
Read More |
|
| 03.10.2010 |
|
Akorn, Inc. Enters into an Agreement to Sell Common Stock and Warrants |
|
Read More |
|
| 02.08.2010 |
|
Akorn, Inc. Announces Fourth Quarter 2009 Earnings Release and Conference Call Information |
|
Read More |
|
